2019-08-30 Assigned to ACADEMIA SINICA reassignment ACADEMIA SINICA
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …

2018-01-29 Assigned to OBI PHARMA, INC. reassignment OBI PHARMA, INC.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …

The present disclosure relates to an α-fucosidase having α-(1, 2), α-(1, 3), α-(1, 4), and α-(1,
6) fucosidase activity. The present disclosure also relates to the compositions comprising the …

2018-06-06 Assigned to ACADEMIA SINICA reassignment ACADEMIA SINICA
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …

4,137.230 A 1/1979 Hashimoto et al. the ikMkk antibodies that have not 4,151,042 A 4/1979
Higashide et al. een glycoengıneered. 4.248. 870 A 2/1981 Miyashita et al. 4,256,746 A …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
60088869&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

4,308,269 A 4,309,428 A 4,313,946 A 4,315,929 A 4,317,821 A 4,322,348 A 4,331,598 A
RE30, 985 E 4,361,650 A 4,362,663 A 4,364,866 A 4,371,533 A 4,376,110 A 4,419,446 A …

US20190389963A1 - Combination therapy by using anti-globo h or anti-ssea-4 antibody with
anti-negative immune check points antibody - Google Patents US20190389963A1 - Combination …

US10918714B2 - Human iNKT cell activation using glycolipids with altered glycosyl groups -
Google Patents US10918714B2 - Human iNKT cell activation using glycolipids with altered …

2020-12-23 Assigned to OBI PHARMA, INC. reassignment OBI PHARMA, INC.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …